UPDATE!!!!!2025/2026|GUARANTEED
Cumulative dose - ANSWER total amount of one antineoplastic agent given to the pt,
adding up each time that the pt has received it
Cumulative lifetime dose - ANSWER -"cumulative dose should not exceed..."-total
amount of specific antineoplastic agents that can be safely given over the course of a pt's
lifetime
-critical to track lifetime dose
Chemotherapy Induced nausea & Vomiting (CINV) - ANSWER -primary prevention
strategy is through consistent use of optimal antiemetic therapy beginning with initial cycle
-prevention is pivotal when attempting to maximize pt quality of life and crucial to
preventing delays in treatment
Two Neural Pathways associated with chemo emetic response - ANSWER 1.Peripheral
pathway
2.central pathway
Two neurotransmitters involved in vomiting - ANSWER 1. serotonin
2. substance P
1
, 5-HT3 receptor antagonists - ANSWER active in peripheral path and counteract acute
nausea and vomiting by blocking serotonin activity
e.g. Aloxi
NK1 dependent mechanism - ANSWER active in central pathway and is active in the
late-acute phase/delayed phase
-substance P acts on NK1 receptors
-Aprepitant
Uncontrolled CINV can cause patient to become: - ANSWER -malnourished
-dehydrated
-electrolyte imbalances
-physical/mental deterioration
-treatment may be delayed or patient may choose to stop beneficial chemo d/t CINV
Risk Factors for CINV (6) - ANSWER 1. Patient age (<50 years)
2. Female sex
3. History of motion sickness
4. History of N/V during pregnancy
5. Poor control of CINV in previous chemo cycles
6. History of chronic alcoholism (DECREASES risk)
Types of CINV - ANSWER -Acute
-Delayed
-Breakthrough
-Anticipatory
-Refractory
2
Cumulative dose - ANSWER total amount of one antineoplastic agent given to the pt,
adding up each time that the pt has received it
Cumulative lifetime dose - ANSWER -"cumulative dose should not exceed..."-total
amount of specific antineoplastic agents that can be safely given over the course of a pt's
lifetime
-critical to track lifetime dose
Chemotherapy Induced nausea & Vomiting (CINV) - ANSWER -primary prevention
strategy is through consistent use of optimal antiemetic therapy beginning with initial cycle
-prevention is pivotal when attempting to maximize pt quality of life and crucial to
preventing delays in treatment
Two Neural Pathways associated with chemo emetic response - ANSWER 1.Peripheral
pathway
2.central pathway
Two neurotransmitters involved in vomiting - ANSWER 1. serotonin
2. substance P
1
, 5-HT3 receptor antagonists - ANSWER active in peripheral path and counteract acute
nausea and vomiting by blocking serotonin activity
e.g. Aloxi
NK1 dependent mechanism - ANSWER active in central pathway and is active in the
late-acute phase/delayed phase
-substance P acts on NK1 receptors
-Aprepitant
Uncontrolled CINV can cause patient to become: - ANSWER -malnourished
-dehydrated
-electrolyte imbalances
-physical/mental deterioration
-treatment may be delayed or patient may choose to stop beneficial chemo d/t CINV
Risk Factors for CINV (6) - ANSWER 1. Patient age (<50 years)
2. Female sex
3. History of motion sickness
4. History of N/V during pregnancy
5. Poor control of CINV in previous chemo cycles
6. History of chronic alcoholism (DECREASES risk)
Types of CINV - ANSWER -Acute
-Delayed
-Breakthrough
-Anticipatory
-Refractory
2
